COMMUNIQUÉS West-GlobeNewswire

LIXTE Biotechnology to Acquire NOMAD Transportable Power Systems, the Market Leader in Mobile, Utility-Grade Battery Energy Storage Systems (BESS)
12/06/2026
Company to be Renamed NOMAD Power Solutions • First-to-Market with the Mobile, Utility-Grade 1 MW BESS • Addressing a Multi-Hundred-Billion-Dollar Power Capacity Opportunity BOCA RATON, Fla. & WATERBURY, Vt., June [...]
BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
12/06/2026
— Growing body of ORLADEYO ® clinical data and real-world evidence demonstrates consistent reductions in HAE attack burden and healthcare utilization across diverse patient populations — New post hoc analysis of Phase [...]
CervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
12/06/2026
BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that [...]
Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting
12/06/2026
Oral presentation at JDA features new data from the KT-621 Phase 1 study in healthy Japanese adults, with safety and PK/PD results consistent with previously reported KT-621 clinical studies KT-621 parallel Phase 2b [...]
Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress
12/06/2026
- JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors - - Selective JAK V617F inhibitor, CGT1145, on track for IND [...]
Profusa Submits Response Package to GMED as Part of Ongoing CE Mark Review Process for Lumee® Oxygen Platform
12/06/2026
BERKELEY, CA, June 12, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, today announces that it has submitted its response package to [...]
Spectral AI Joins the American Board of Wound Management Foundation in Celebrating Wound Healing Awareness Month
12/06/2026
DALLAS, June 12, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”) , an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment [...]
Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting
12/06/2026
Data from the RALLY-MF trial of DISC-0974 in patients with myelofibrosis (MF) and anemia demonstrate meaningful, durable overall anemia responses across all patient subgroups, regardless of baseline transfusion status [...]
Recludix Pharma to Present Preclinical Asthma and Dermatitis Data for Oral STAT6 Inhibitor REX-8756 at the European Association of Allergy and Clinical Immunology (EAACI) and Revolutionizing Atopic Dermatitis (RAD) Congresses
12/06/2026
SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today announced preclinical [...]
Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress
12/06/2026
-- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an updated objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria – -- Bezuclastinib [...]
Le KFSH fait progresser les applications pratiques de l’IA pour transformer les soins de santé spécialisés
12/06/2026
RIYAD, Arabie saoudite, 12 juin 2026 (GLOBE NEWSWIRE) -- Le King Faisal Specialist Hospital & Research Centre (KFSH) mettra en avant ses applications pratiques de l’intelligence artificielle lors de sa participation [...]
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
12/06/2026
Rhapsido demonstrated statistically significant and clinically meaningful symptom control in twice as many patients vs placebo 1 , with favorable safety profile and no observed liver safety concerns 2 With global CIndU [...]
Evaxion receives Prix Galien UK Award for Best digital health solution
12/06/2026
COPENHAGEN, Denmark, June 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, has been awarded the 2026 Prix Galien [...]
EAACI Calls for a "Vision Zero" Future Free from Allergy and Asthma Burden
12/06/2026
Leading allergy experts to convene in Istanbul to explore how science, prevention and policy can reduce the global impact of allergic diseases ZURICH, June 12, 2026 (GLOBE NEWSWIRE) -- As allergic diseases continue to [...]
Arcadia Biosciences (RKDA) Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
12/06/2026
DALLAS, June 11, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc . ® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, announced today that it has entered into securities purchase agreements for [...]
Gen Z Is Redefining the Medical Aesthetics Patient Journey, New Guidepoint Qsight Study Finds
12/06/2026
New York, NY, June 11, 2026 (GLOBE NEWSWIRE) -- Leaping Straight to Neurotoxin Treatments like Botox and Dysport, NextGen Medical Aesthetics Patients Frequently Skip Lower Commitment Services Qsight patient transaction [...]
HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress
12/06/2026
— Sovleplenib demonstrated rapid and durable hemoglobin response with favorable safety profile — —The ESLIM-02 study underscores sovleplenib’s potential to address critical unmet needs in a treatment landscape currently [...]
Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference
11/06/2026
LEXINGTON, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that Alfred W. [...]
Nanox to Report First Quarter 2026 Financial Results on June 25, 2026
11/06/2026
PETACH TIKVA, Israel, June 11, 2026 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company", Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will report its financial [...]

Pages